Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 3
Submit an article Journal homepage
454
Views
31
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma

Morton Coleman Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USACorrespondence[email protected]
,
Peter Martin Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
,
Jia Ruan Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
,
Richard Furman Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
,
Ruben Niesvizky Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
,
Rebecca Elstrom Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
,
Patricia George Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
,
John Leonard Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
&
Thomas Kaufmann Division of Hematology – Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
 show all
Pages 447-450 | Received 18 Oct 2007, Accepted 01 Dec 2007, Published online: 01 Jul 2009

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Martin Dreyling, Igor Aurer, Sergio Cortelazzo, Olivier Hermine, Georg Hess, Mats Jerkeman, Steven Le Gouill, Vincent Ribrag, Marek Trněný, Carlo Visco, Jan Walewski, Francesco Zaja & Pier Luigi Zinzani. (2018) Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia & Lymphoma 59:8, pages 1814-1828.
Read now
Nishanth Vallumsetla, Jonas Paludo & Prashant Kapoor. (2015) Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. Therapeutics and Clinical Risk Management 11, pages 1663-1674.
Read now
Fan Zhou, Chenhui Ling, Lieping Guo, Wei Wei, Lu Li, Haotian Shi & Jian Hou. (2014) Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure. Leukemia & Lymphoma 55:10, pages 2271-2276.
Read now
Morton Coleman, Gia Ruan, Elstrom Rebecca L.Peter Martin & John P. Leonard. (2012) Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology 17:sup1, pages s90-s92.
Read now
Sotirios Sachanas, Gerassimos A. Pangalis, Theodoros P. Vassilakopoulos, Penelope Korkolopoulou, Flora N. Kontopidou, Maria Athanasoulia, Xanthi Yiakoumis, Christina Kalpadakis, Georgios Georgiou, Stavroula Masouridis, Maria Moschogiannis, Pantelis Tsirkinidis, Vassiliki Pappis, Styliani I. Kokoris, Marina P. Siakantaris, Panayiotis Panayiotidis & Maria K. Angelopoulou. (2011) Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leukemia & Lymphoma 52:3, pages 387-393.
Read now
David P Samuel, Patrick Y Wen & Mark W Kieran. (2009) Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opinion on Investigational Drugs 18:7, pages 973-983.
Read now
Mark Prichard, Thomas Harris, Michael E Williams & John J Densmore. (2009) Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. Expert Opinion on Pharmacotherapy 10:6, pages 983-995.
Read now

Articles from other publishers (24)

Simon J. Bulley, Anna Santarsieri, Isabel C. Lentell, Brendan O'Sullivan, Andrew Hodson, Oliver Firth, Shalal Sadullah, Annabel M. Follows, Mamatha Karanth, Sandra Young Min, Alexis Fowler, James Russell, Benjamin J. Uttenthal, Daniel J. Hodson & George A. Follows. (2022) Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study. eJHaem 3:4, pages 1316-1320.
Crossref
Kathleen O'Connell, Maurine Thomson, Elizabeth Morgan & Joerg Henning. (2022) Procarbazine, prednisolone and cyclophosphamide oral combination chemotherapy protocol for canine lymphoma. Veterinary and Comparative Oncology 20:3, pages 613-622.
Crossref
Vivek Sulekha Radhakrishnan, Padmaja Lokireddy, Mayur Parihar, Prashanth Srirangapattana Prakash & Hari Menon. (2021) Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. Cancer Reports 5:7.
Crossref
Fen Saj, Amit Kumar Deb, Subhashini Kaliaperumal, Smita Kayal, Biswajit Dubashi, Rahul Dhodapkar & Prasanth Ganesan. (2022) Bilateral CMV Retinitis in a Patient with Relapsed Non-Hodgkin Lymphoma on Oral Metronomic Chemotherapy: Case Report and Review of Literature. Indian Journal of Medical and Paediatric Oncology.
Crossref
Vadakkepurath Raj Athira, Madathiparambil Karthikeyan Saranya, Thimmappa Shivanandappa & Hanumant Narasinhacharya Yajurvedi. (2019) Multiple dose treatment reduces cyclophosphamide‐induced ovarian follicular loss in mice. Birth Defects Research 112:1, pages 71-80.
Crossref
Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman & Sara Ek. (2018) Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity. BMC Cancer 18:1.
Crossref
Pamela McKay, Mike Leach, Bob Jackson, Stephen Robinson & Simon Rule. (2018) Guideline for the management of mantle cell lymphoma. British Journal of Haematology 182:1, pages 46-62.
Crossref
Vanita Noronha, Vijay M. Patil, Amit Joshi, Anuradha Chougule, Shripad Banavali & Kumar Prabhash. (2017) Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer. Cancer Letters 400, pages 267-275.
Crossref
Sarah Wall & Jennifer A. Woyach. (2016) Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. Clinics in Geriatric Medicine 32:1, pages 175-189.
Crossref
Keyur Thakar, Aileen Novero, Arundhati Das, Adriana Lisinschi, Bella Mehta, Tauseef Ahmed & Delong Liu. (2014) CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomarker Research 2:1.
Crossref
Betty M. Chan & Agustin A. Garcia. (2014) Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Breast Diseases: A Year Book Quarterly 25:1, pages 18-20.
Crossref
Keemo Delos Santos, Kelly Lien, Soley Georgsdottir, Lavarnan Sivanathan & Urban Emmenegger. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy 263 279 .
Pannee Praditsuktavorn & Jia Ruan. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy 173 188 .
P. McKay, M. Leach, R. Jackson, G. Cook & S. Rule. (2012) Guidelines for the investigation and management of mantle cell lymphoma. British Journal of Haematology 159:4, pages 405-426.
Crossref
Nicolas Penel, Antoine Adenis & Guido Bocci. (2012) Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?. Critical Reviews in Oncology/Hematology 82:1, pages 40-50.
Crossref
K Mross & S Steinbild. (2012) Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients. journal of Cancer Therapeutics and Research 1:1, pages 32.
Crossref
Andre Goy. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies 308 337 .
I. Zenker, K. Meichner, K. Steinle, M. Kessler & J. Hirschberger. (2010) Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs. Veterinary Record 167:19, pages 744-748.
Crossref
Jia Ruan, Peter Martin, Morton Coleman, Richard R. Furman, Ken Cheung, Adam Faye, Rebecca Elstrom, Mark Lachs, Katherine A. Hajjar & John P. Leonard. (2010) Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 116:11, pages 2655-2664.
Crossref
Rosemary Rochford & Scot C. Remick. 2010. Molecular Basis for Therapy of AIDS-Defining Cancers. Molecular Basis for Therapy of AIDS-Defining Cancers 199 210 .
Anna Fioravanti, Bastianina Canu, Greta Alì, Paola Orlandi, Giacomo Allegrini, Teresa Di Desidero, Urban Emmenegger, Gabriella Fontanini, Romano Danesi, Mario Del Tacca, Alfredo Falcone & Guido Bocci. (2009) Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. European Journal of Pharmacology 619:1-3, pages 8-14.
Crossref
Michele Ghielmini & Emanuele Zucca. (2009) How I treat mantle cell lymphoma. Blood 114:8, pages 1469-1476.
Crossref
J. Ruan, K. Hajjar, S. Rafii & J.P. Leonard. (2009) Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Annals of Oncology 20:3, pages 413-424.
Crossref
Morton Coleman, Peter Martin, Jia Ruan, Richard Furman, Ruben Niesvizky, Rebecca Elstrom, Patricia George, Thomas P. Kaufman & John P. Leonard. (2008) Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low-dose metronomic, multidrug therapy. Cancer 112:10, pages 2228-2232.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.